| 000 | 01689cam a2200277 4500500 | ||
|---|---|---|---|
| 005 | 20250112064024.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aMoradian, Negar _eauthor |
| 700 | 1 | 0 |
_a Gouravani, Mahdi _eauthor |
| 700 | 1 | 0 |
_a Salehi, Mohammad Amin _eauthor |
| 700 | 1 | 0 |
_a Heidari, Arash _eauthor |
| 700 | 1 | 0 |
_a Shafeghat, Melika _eauthor |
| 700 | 1 | 0 |
_a Hamblin, Michael R. _eauthor |
| 700 | 1 | 0 |
_a Rezaei, Nima _eauthor |
| 245 | 0 | 0 | _aCytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality |
| 260 | _c2020. | ||
| 500 | _a14 | ||
| 520 | _aCoronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patients in comparison with mildly affected patients suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha, and their mechanism of action in the CRS cascade is explained. Potential therapeutic approaches involving anti-IL-6 and anti-TNF-alpha antibodies to fight COVID-19 and reduce mortality rate in severe cases are also discussed. | ||
| 690 | _aCOVID-19 | ||
| 690 | _aCorona virus | ||
| 690 | _acytokine release syndrome | ||
| 690 | _atreatment | ||
| 786 | 0 | _nEuropean Cytokine Network | Volume 31 | 3 | 2020-09-01 | p. 81-93 | 1148-5493 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-european-cytokine-network-2020-3-page-81?lang=en |
| 999 |
_c236171 _d236171 |
||